Transgender Medicine AND Hormone Therapy — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Transgender Medicine AND Hormone Therapy.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Transgender Medicine AND Hormone Therapy and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Hastie E, Khetan P, LaMere SA, George AF, et al. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies Am J Reprod Immunol, 2026.PMID 42461585
[2]Yoon JW, Kim G, Lee ES, Lee SY, et al. Cervical cancer screening and HPV vaccination among assigned female at birth transgender and gender-diverse individuals in South Korea: findings from the KITE cohort BMC Public Health, 2026.PMID 42437894
[3]Thomas TA, Winston-McPherson GN, Amarillo I, Berry AD, et al. ADLM Guidance Document on Incorporating Gender Diversity in Pathology and Laboratory Medicine J Appl Lab Med, 2026.PMID 42383916
[4]Hastie E, Bortner A, Wagner GA, Blumenthal J Gender-Affirming Medical Treatment of Transgender and Gender-Diverse Individuals Obstet Gynecol Clin North Am, 2026.PMID 42236065
[5]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[6]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
[7]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
[8]Weiß A, Haussmann J, Goeckenjan M Establishing a Transgender Outpatient Clinic Within the Gynaecology Department: a Retrospective Analysis of the First Few Years Geburtshilfe Frauenheilkd, 2026.PMID 42459842

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Transgender Medicine AND Hormone Therapy and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Hastie E, Khetan P, LaMere SA, George AF, et al. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies Am J Reprod Immunol, 2026.PMID 42461585
[2]Yoon JW, Kim G, Lee ES, Lee SY, et al. Cervical cancer screening and HPV vaccination among assigned female at birth transgender and gender-diverse individuals in South Korea: findings from the KITE cohort BMC Public Health, 2026.PMID 42437894
[3]Thomas TA, Winston-McPherson GN, Amarillo I, Berry AD, et al. ADLM Guidance Document on Incorporating Gender Diversity in Pathology and Laboratory Medicine J Appl Lab Med, 2026.PMID 42383916
[4]Hastie E, Bortner A, Wagner GA, Blumenthal J Gender-Affirming Medical Treatment of Transgender and Gender-Diverse Individuals Obstet Gynecol Clin North Am, 2026.PMID 42236065
[5]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[6]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
[7]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
[8]Weiß A, Haussmann J, Goeckenjan M Establishing a Transgender Outpatient Clinic Within the Gynaecology Department: a Retrospective Analysis of the First Few Years Geburtshilfe Frauenheilkd, 2026.PMID 42459842